source
- Experimental drugs to lower Lp(a) move toward market, promising billions in potential salesHigh levels of lipoprotein(a), or Lp(a), are a genetic risk factor for heart disease that affects roughly one in five people and currently has no approved therapy. Several drugmakers are moving ex…
- Vitruvias Therapeutics shuts down after recalling potentially superpotent thyroid tabletsVitruvias Therapeutics announced it is ceasing operations and has voluntarily recalled a batch of its generic thyroid tablets because the product may be superpotent. The recall covers 3,655 units…